4/25/2013

Researchers found osteoporosis drug zoledronic acid increases levels of a biomarker that inhibits bone formation in postmenopausal women. The study was published in the Journal of Clinical Endocrinology & Metabolism. Lead author Antonino Catalano, M.D., said patients who use zoledronic acid may need other treatments to allow for new bone formation.

Full Story:
AAFP News

Related Summaries